Interferon-Tau has Antiproliferative effects, Represses the Expression of E6 and E7 Oncogenes, Induces Apoptosis in Cell Lines Transformed with HPV16 and Inhibits Tumor Growth <i>In Vivo</i>

Padilla-Quirarte, Herbey Oswaldo; Trejo-Moreno, Cesar; Fierros-Zarate, Geny; Castañeda, Jhoseline Carnalla; Palma-Irizarry, M.; Hernández-Márquez, Eva; Burguete-García, Ana I.; Peralta‐Zaragoza, Oscar; Madrid‐Marina, Vicente; Torres-Poveda, Kirvis; Bermúdez-Morales, Víctor Hugo

doi:10.7150/jca.15502

Cited by 10 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent finding showed that IFN-τ has antiviral activity and antiproliferative effects on tumor cells. It also displays a cross-species activity in humans, mice and ruminants, and it lacks the associated toxicity of other interferons [14,15]. The fact that exogenous ovine IFN-τ has antiviral and antiproliferative effects on HPV16-positive murine and human cells is also correlated to the tumor inhibition in a cervical cancer experimental model [14], and it is linked to the activity of IFN-τ on the permissibility of tumor cells and signal transduction.…”

Section: Discussionmentioning

confidence: 99%

“…It also displays a cross-species activity in humans, mice and ruminants, and it lacks the associated toxicity of other interferons [14,15]. The fact that exogenous ovine IFN-τ has antiviral and antiproliferative effects on HPV16-positive murine and human cells is also correlated to the tumor inhibition in a cervical cancer experimental model [14], and it is linked to the activity of IFN-τ on the permissibility of tumor cells and signal transduction. In order to determine which downstream signaling molecules are involved in the HPV16-transformed epithelial cells, we examined the effects of the ovine interferon on the JAK-STATprotein profiling and on the phosphorylation profiling of BMK-16/myc cells.…”

Section: Discussionmentioning

confidence: 99%

“…A murine HPV 16-transformed BMK-16/myc cell line, which produces tumors in immunocompetent mice [13,14], was established by co-transformation of baby Balb/c kidney cells with the c-myc gene and the HPV 16 genome. The cell line was cultured in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% of fetal bovine serum (FBS) (Gibco, ThermoFisher Scientific, Waitham, MA, USA), ampicillin, streptomycin and amphotericin (Caisson), at 37ºC in 95% humidity with 5% CO2.…”

Section: Cell Lines and Chemicalsmentioning

confidence: 99%

See 2 more Smart Citations

Bovine Interferon-Tau Activates Type I interferon-Associated Janus-signal Transducer in HPV16-positive Tumor Cell

et al. 2020

Self Cite

View full text Add to dashboard Cite

The mechanisms of signal transduction by interferon-tau (IFN-τ) are widely known during the gestation of ruminants. In trophoblast cells, IFN-τ involves the activation of the JAK-STAT pathway, and it can have effects on other cell types, such as tumor cells. Here we report that the HPV16-positive BMK-16/myc cell treated with ovine IFN-τ, results in the activation of the canonical JAK-STAT and non-canonical JAK-STAT pathway. The MAPK signaling pathway was activated, we detected the proteins MEK1, MEK2, Raf1, STAT3, STA4, STAT5 and STAT6. Moreover, IFN-τ induced the expression of MHC Class I, MX and IP10 in the tumor cells and this response may be associated with the viral replication and with the anti-proliferative and the immunoregulatory effects of IFN-τ.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Cell Lines and Chemicalsmentioning

confidence: 99%

See 1 more Smart Citation

Bovine Interferon-Tau Activates Type I interferon-Associated Janus-signal Transducer in HPV16-positive Tumor Cell

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The alterations of protein-coding genes and signaling pathways in the initiation and progression of cervical cancer have been well recognized 36, 37. The implications of lncRNAs in cervical cancer are relative much less recognized.…”

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA GIHCG functions as an oncogene and serves as a serum diagnostic biomarker for cervical cancer

Zhang¹,

Mao²,

et al. 2019

J. Cancer

View full text Add to dashboard Cite

Cervical cancer is the most common and lethal gynaecological tumor. Long noncoding RNAs (lncRNAs) have critical roles in various cancers, including cervical cancer. However, few studies investigated the diagnostic value of lncRNAs for cervical cancer. In this study, we investigated the expression pattern of a recently identified lncRNA GIHCG in cervical cancer tissues, cell lines, and serums by qRT-PCR. Furthermore, we explored the roles of GIHCG in cervical cancer using gain-of-function and loss-of-function assays. Our results revealed that GIHCG is up-regulated in cervical cancer tissues and cell lines compared with adjacent normal tissues and normal cervical epithelial cell line, respectively. Furthermore, serum GIHCG is significantly up-regulated in cervical cancer patients compared with healthy controls. ROC curve analysis revealed that serum GIHCG could accurately discriminate cervical cancer patients from healthy controls. Functionally, we found that overexpression of GIHCG promotes cell proliferation, inhibits cell apoptosis, and promotes cell migration of cervical cancer cells. Conversely, depletion of GIHCG inhibits cell proliferation, induces cell apoptosis, and inhibits cell migration of cervical cancer cells. Mechanistically, we found that GIHCG represses the expression of miR-200b. The expression of miR-200b is inversely correlated with the expression of GIHCG in cervical cancer tissues. Moreover, overexpression of miR-200b attenuates the roles of GIHCG in promoting cervical cancer tumor growth in vivo. In summary, this study demonstrated that GIHCG functions as an oncogene in cervical cancer via repressing miR-200b. This study also suggested that GIHCG may be a non-invasive diagnostic biomarker and a potential therapeutic target for cervical cancer.

show abstract

“…It has been shown that viral infection triggers the activation of IFN receptor 9 (IRF9) forming a complex (ISGF3 complex) that translocates to the nucleus and binds to specific regulatory DNA sequences interfering with the transcription of many IFN-stimulated genes (ISGs). 68 Table 2 summarizes the immunologic activity of HPV proteins.…”

Section: Introductionmentioning

confidence: 99%

Head and neck cancer: improving outcomes with a multidisciplinary approach

Nigro¹,

Denaro²,

Merlotti³

et al. 2017

CMAR

180

126

View full text Add to dashboard Cite

For early-stage head and neck cancer (HNC), surgery (S) or radiotherapy (RT) is a standard treatment. The multidisciplinary approach, which includes multimodality treatment with S followed by RT, with or without chemotherapy (CT) or concurrent chemoradiotherapy (CRT), is required for locally advanced head and neck cancer (LAHNC). CRT improves prognosis, locoregional control (LRC), and organ function in LAHNC, compared to RT alone. Prognosis in recurrent/metastatic HNC (R/M HNC) is dismal. Platinum-based CT, combined with the anti-Epidermal Growth Factor Receptor (EGFR) antibody (Ab) cetuximab, is used in first-line setting, while no further validated options are available at progression. The complexity of disease is, in part, due to the heterogeneity of organs and functions involved and the need for a multimodality approach. In addition, the patient population (often elderly and/or patients with smoking and alcohol habits) argues for an individually tailored treatment plan. Furthermore, treatment goals – which include cure, organ, and function preservation, quality of life and palliation – must also be considered. Thus, optimal management of patients with HNC should involve a range of healthcare professionals with relevant expertise. The purpose of the present review is to 1) highlight the importance and necessity of the multidisciplinary approach in the treatment of HNC; 2) update the knowledge regarding modern surgical techniques, new medical and RT treatment approaches, and their combination; 3) identify the treatment scenario for LAHNC and R/M HNC; and 4) discuss the current role of immunotherapy in HNC.

show abstract

Interferon-Tau has Antiproliferative effects, Represses the Expression of E6 and E7 Oncogenes, Induces Apoptosis in Cell Lines Transformed with HPV16 and Inhibits Tumor Growth In Vivo

Cited by 10 publications

References 32 publications

Bovine Interferon-Tau Activates Type I interferon-Associated Janus-signal Transducer in HPV16-positive Tumor Cell

Bovine Interferon-Tau Activates Type I interferon-Associated Janus-signal Transducer in HPV16-positive Tumor Cell

Long noncoding RNA GIHCG functions as an oncogene and serves as a serum diagnostic biomarker for cervical cancer

Head and neck cancer: improving outcomes with a multidisciplinary approach

Contact Info

Product

Resources

About